Freeline Therapeutics Stock

freeline.lifeHealthcareFounded: 2015Funding to Date: $205.53MM

Freeline is a clinical-stage, fully integrated, next generation, systemic AAV-based gene therapy company with the ambition of transforming the lives of patients suffering from inherited systemic debilitating diseases.

Register for Details

For more details on financing and valuation for Freeline Therapeutics, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

Enterprise Value (based on primary financings)

Powered by Forge Data
Enterprise Value

View Enterprise Value for Freeline Therapeutics.

Register Today


Management Team

Brian Silver JD
Chief Financial Officer & Head of Corporate Development
Karen Law
Natalia Misciattelli
Senior Vice President, Strategy and Business Operations
Markus Horer Ph.D
Co-Founder, Chief Technology Officer & Managing Director
Jane Whitrow Ph.D
Vice President, Finance & Company Secretary
Jan Thirkettle Ph.D
Chief Development Officer
Amit Nathwani
Co-Founder, Chief Scientific Officer & Board Member
Gerard Short
Senior Vice President, Head of Clinical and Regulatory
Romuald Corbau Ph.D
Vice President, Research

Board Members

Christopher Hollowood Ph.D
Amit Nathwani
Martin Andrews
Jeffrey Chodakewitz MD

Other companies like Freeline Therapeutics in the Healthcare sector

Last Round Est. Valuation
Last Round Est. Valuation
Last Round Est. Valuation
Last Round Est. Valuation
Last Round Est. Valuation